Cervical Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against cervical cancer and guarantee the finest results for our customers all over the world.

Cervical Cancer

On a global scale, approximately one in six new cancer diagnoses is attributable to an infectious pathogen. HPVs cause approximately 30% of malignancies attributable to specific infections, including cancers of the cervix, vagina, vulva, anus, and oropharynx. Despite the existence of preventive HPV vaccines and screening methods to detect HPV, cervical cancer remains the second largest cause of cancer mortality in women in low resource settings.

HPV infects cervical epithelium shortly after sexual debut and can be detected in up to 50% of young women who have initiated sexual intercourse in the preceding 36 months. Infections are asymptomatic, and although most are transient, resolution can take 1 to 2 years. Older women take longer to clear infections, as do smokers and women with underlying immunosuppression. The existing prophylactic vaccines have no therapeutic effect.

Preventative Vaccines for Cervical Cancer

Current methods for preventing HPV disease include screening, using either cytology or HPV testing, or a combination of both. Prophylactic vaccines that protect against infection with oncogenic HPV genotypes are comprised of noninfective recombinant virus-like particles (VLPs) of L1, one of the two HPV capsid proteins. These VLPs do not contain viral DNA, and thus are completely noninfectious and nononcogenic. All are highly effective against HPV infections not only in the cervix but also other anatomical sites, in both sexes. These vaccines elicit robust antibody responses that are 1 to 2 logs greater than those elicited by natural infection. In persons known to have been previously exposed to HPV, a single vaccination with qHPV drastically enhanced both the magnitude and the quality of the antibody response. In contrast to the nonneutralizing antibodies generated by natural infections, antibodies elicited by vaccination were neutralizing.

Therapeutic Vaccines for Cervical Cancer

In contrast to the prophylactic vaccines, the development of new therapeutic vaccines is focused on targeting E6 and E7. Effector T cell responses to these viral, non-self oncoproteins, which are constitutively expressed by transformed cells, are likely to play a role in mediating lesion regression. Several vaccine platforms have been evaluated, including naked DNA; DNA administered with electroporation; viral vectors vaccine, including modified vaccinia Ankara (MVA) and vaccinia virus; peptides administered with adjuvant; and bacterial constructs, such as Listeria monocytogenes. Despite promising data derived from preclinical models, translation to humans has been modest. To date, vaccine-induced immune responses in humans with any stage of HPV disease have been minimal.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the cervical cancer vaccines. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.